mAbs · 2013 · 85 citations · 28 references
Life SciencesBiochemistryImmunologyMass Spectrometric AnalysisMonoclonal AntibodiesProteomicsAntibody CharacterizationGlycoproteomicsMass Spectrometry-based ProteomicsPeptide AnalysisProtein IdentificationProteomic Quality ControlAnalytical Methods DevelopmentAntibody GlycoformsCapillary ElectrophoresisMass Spectrometry-based Protein IdentificationProtein Mass SpectrometrySingle ShotTandem Mass SpectrometryTandem Mass Spectrometry Analysis
Monoclonal antibodies (mAbs) are highly complex proteins that display a wide range of microheterogeneity that requires multiple analytical methods for full structure assessment and quality control. As a consequence, the characterization of mAbs on different levels is particularly product - and time - consuming. This work presents the characterization of trastuzumab sequence using sheathless capillary electrophoresis (referred as CESI) - tandem mass spectrometry (CESI-MS/MS). Using this bottom-up proteomic-like approach, CESI-MS/MS provided 100% sequence coverage for both heavy and light chain via peptide fragment fingerprinting (PFF) identification. The result was accomplished in a single shot, corresponding to the analysis of 100 fmoles of digest. The same analysis also enabled precise characterization of the post-translational hot spots of trastuzumab, used as a representative widely marketed therapeutic mAb, including the structural confirmation of the five major N-glycoforms.
28
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Paul Carter, Leonard G. Presta, C Gorman et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations
Marketed therapeutic antibodies compendium
Janice M. Reichert · mAbs · 2012 · 367 citations · Full text
Pharmacy, Immunology, Pharmacology +17